

Supplementary

Table S1. Clinicopathologic features of the tumors. BCRL, breast cancer related lymphedema; ER, estrogen receptor; PR, progesterone receptor; LN, lymph nodes.

	BCRL+ (<i>n</i> = 75)	BCRL- (<i>n</i> = 293)	<i>p</i> -Value
Side, right <i>n</i> (%)	48 (64.0)	142 (48.6)	0.0163
Histotype, <i>n</i> (%)			0.0964
No special type (ductal)	67 (89.3)	238 (81.2)	
Other	8 (10.7)	55 (18.8)	
pT, <i>n</i> (%)			0.8501
T1	43 (57.3)	168 (57.3)	
T2	25 (33.3)	91 (31.1)	
T3	3 (4.0)	10 (3.4)	
T4	4 (5.3)	24 (8.2)	
pN, <i>n</i> (%)			0.1405
N1	40 (53.3)	192 (65.5)	
N2	18 (24.0)	55 (18.8)	
N3	17 (22.7)	46(15.7)	
Grade, <i>n</i> (%)			0.4122
1	3 (4.00)	25 (8.5)	
2	40 (53.3)	146 (49.8)	
3	32 (42.7)	122 (41.6)	
ER+, <i>n</i> (%)	64 (85.3)	263 (89.8)	0.2768
PR+, <i>n</i> (%)	58 (77.3)	242 (82.6)	0.2949
HER2+, <i>n</i> (%)	11 (14.7)	26 (8.9)	0.1366
Ki67-high, <i>n</i> (%)	36 (48.0)	120 (41.0)	0.2707
Receptor status, <i>n</i> (%)			0.1265
ER+, HER2-	56 (74.7)	248 (84.6)	
HER2+	11 (14.7)	26 (8.9)	
ER-, HER2-	8 (10.7)	19 (6.5)	
Lymphovascular invasion, <i>n</i> (%)	33 (44.0)	85 (29.0)	0.0131
Extranodal extension, <i>n</i> (%)	57 (76.0)	180 (61.4)	0.0187
Nr. metastatic LN, median (Q1; Q3)	3 (1; 7)	2 (1; 5)	0.0434
Total nr. of LN, median (Q1; Q3)	23 (18; 29)	23 (19; 30)	0.4854
% metastatic LN, median (Q1; Q3)	13 (6; 30)	10 (5; 25)	0.2573